Exposure to ASCVD risk from Lp(a) may have “primed” patients for higher MACE and MALE after endovascular therapy, editorialist notes.
Exposure to ASCVD risk from Lp(a) may have “primed” patients for higher MACE and MALE after endovascular therapy, editorialist notes.
In the news: Lipoprotein(a)